CN102300582A - 用于治疗阿尔茨海默病的化合物和方法 - Google Patents

用于治疗阿尔茨海默病的化合物和方法 Download PDF

Info

Publication number
CN102300582A
CN102300582A CN201080005669XA CN201080005669A CN102300582A CN 102300582 A CN102300582 A CN 102300582A CN 201080005669X A CN201080005669X A CN 201080005669XA CN 201080005669 A CN201080005669 A CN 201080005669A CN 102300582 A CN102300582 A CN 102300582A
Authority
CN
China
Prior art keywords
seq
ctprosp
people
albumen
described isolating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080005669XA
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·约翰森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AlphaBeta AB
Original Assignee
AlphaBeta AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlphaBeta AB filed Critical AlphaBeta AB
Publication of CN102300582A publication Critical patent/CN102300582A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080005669XA 2009-01-30 2010-01-29 用于治疗阿尔茨海默病的化合物和方法 Pending CN102300582A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14854109P 2009-01-30 2009-01-30
EP09151790.4 2009-01-30
US61/148,541 2009-01-30
EP09151790 2009-01-30
PCT/SE2010/050097 WO2010087771A1 (en) 2009-01-30 2010-01-29 Compound and method for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN102300582A true CN102300582A (zh) 2011-12-28

Family

ID=40707673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080005669XA Pending CN102300582A (zh) 2009-01-30 2010-01-29 用于治疗阿尔茨海默病的化合物和方法

Country Status (5)

Country Link
US (2) US8785390B2 (enExample)
EP (1) EP2391379B1 (enExample)
JP (1) JP5801206B2 (enExample)
CN (1) CN102300582A (enExample)
WO (1) WO2010087771A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
EP2694977B1 (en) * 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN114107254A (zh) * 2021-11-12 2022-03-01 武汉理工大学 一种重组蛋白DspB-SNa5及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224982A1 (en) * 2001-07-05 2003-12-04 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN1764457A (zh) * 2003-04-04 2006-04-26 默克.夏普-道姆公司 用于治疗阿尔茨海默病的联合疗法
WO2009009396A2 (en) * 2007-07-06 2009-01-15 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290516A4 (en) 1986-10-24 1989-11-14 Jeffrey A Whitsett PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES.
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6716589B2 (en) 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
MXPA04010560A (es) * 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
CA2507613A1 (en) 2002-12-09 2004-07-08 Jeffrey A. Whitsett Methods of diagnosis and treatment of interstitial lung disease
DE602004008658T2 (de) 2003-09-05 2008-06-12 Cellzome Ag Behandlung neurodegenerativer krankheiten
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
CA2549160A1 (en) 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
KR100992492B1 (ko) 2004-04-05 2010-11-08 토쿠시마 대학 국소 점막 면역 유도 촉진용 항원약물 비히클, 이것을 사용하는 점막 백신, 알레르기의 예방제 또는 치료제, 약물전달 시스템, 및 점막면역의 유도방법
JP2008546701A (ja) 2005-06-14 2008-12-25 イェシバ・ユニバーシティ Ａβ産生へのＢＲＩ蛋白の効果
WO2007005672A2 (en) 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
EP2096910A4 (en) 2006-11-22 2011-11-30 Einstein Coll Med Transgenic mammals modified bri protein expression
CN101754747A (zh) 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
EP2694977B1 (en) 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224982A1 (en) * 2001-07-05 2003-12-04 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN1764457A (zh) * 2003-04-04 2006-04-26 默克.夏普-道姆公司 用于治疗阿尔茨海默病的联合疗法
WO2009009396A2 (en) * 2007-07-06 2009-01-15 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLOTTE NERELIUS等: "Mutations linked to interstitial lung disease can abrogate anti-amyloid function of prosurfactant protein C", 《BIOCHEM. J.》 *
CHRISTOPHER G. EVANS等: "Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1-42) Aggregation in Vitro", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
LUIS SÁNCHEZ-PULIDO等: "BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer", 《TRENDS IN BIOCHEMICAL SCIENCES》 *

Also Published As

Publication number Publication date
EP2391379A1 (en) 2011-12-07
WO2010087771A1 (en) 2010-08-05
US20140243272A1 (en) 2014-08-28
JP5801206B2 (ja) 2015-10-28
US8785390B2 (en) 2014-07-22
EP2391379B1 (en) 2017-08-02
JP2012521346A (ja) 2012-09-13
WO2010087771A8 (en) 2011-08-25
US20120122794A1 (en) 2012-05-17
EP2391379A4 (en) 2012-11-28
US9402883B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
JP5893614B2 (ja) アルツハイマー病および家族性認知症の治療のための化合物および方法
EP2891661B1 (en) Mitochondrial targeting peptide
US11952432B2 (en) Cell-permeable stapled peptide modules for cellular delivery
US10683333B2 (en) Islet amyloid polypeptides with improved solubility
Nerelius et al. Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid β-peptide and medin
US9402883B2 (en) Compound and method for treatment of Alzheimer's disease
JP2025163012A (ja) レトロインベルソペプチド
US20240294572A1 (en) Antimicrobial Peptides
EP3774858B1 (en) C-terminal cdnf fragments having neuroprotective effect
JP6227523B2 (ja) 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット
JP6258282B2 (ja) アルツハイマー病および家族性認知症の治療のための化合物および方法
US9809627B2 (en) Cyclized transthyretin peptide and methods of use therefor
KR20260035939A (ko) Klk1 융합 단백질을 제조하는 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20111228

RJ01 Rejection of invention patent application after publication